

#1  
Comp. + 91  
G1

wherein said polypeptide is expressed *in vivo* in muscle cells and is distributed throughout the muscle mass;  
and (ii) a pharmaceutically acceptable carrier.

112, 2 and

Please add the following new Claim:

F2

22. (New) A composition consisting essentially of (i) a non replicative recombinant adenoviral vector wherein said non replicative recombinant adenoviral vector comprises a heterologous polynucleotide sequence encoding a polypeptide, which polynucleotide sequence is inserted into a deleted E1 region of said non replicative recombinant adenoviral vector and is under the control of a promoter selected from the promoter contained in the Long Terminal Repeat of Rous Sarcoma Virus, the promoter of the  $\beta$  gene of cytomegalovirus, the Mouse Mammary Tumor Virus inducible promoter and the metallothionine promoter wherein said polypeptide is expressed *in vivo* in muscle cells and is distributed throughout the muscle mass;  
and (ii) a pharmaceutically acceptable carrier.